Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

24.97 -0.19 (-0.76%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
News headline image
Apellis' Pegcetacoplan Showed Continuous, Meaningful Effects At Month 18 In Geographic Atrophy Studies ↗
 
Via Benzinga
News headline image
Here's Why Apellis Pharmaceuticals Shares Are Rising ↗
Apellis Pharmaceuticals Inc (NASDAQ: APLS) shares are trading higher by 8.6% at $43.49 after the company announced Pegcetacoplan showed continuous and clinically meaningful effects at month 18 in Phase... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
Expert Ratings For Apellis Pharmaceuticals ↗
Over the past 3 months, 4 analysts have published their opinion on Apellis Pharmaceuticals (NASDAQ:APLS) stock. These analysts are typically employed by large Wall Street banks... 
Via Benzinga
News headline image
Where Apellis Pharmaceuticals Stands With Analysts ↗
Apellis Pharmaceuticals (NASDAQ:APLS) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish... 
Via Benzinga
News headline image
Earnings Scheduled For February 28, 2022 ↗
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (... 
Via Benzinga
News headline image
Where Apellis Pharmaceuticals Stands With Analysts ↗
Analysts have provided the following ratings for Apellis Pharmaceuticals (NASDAQ: 
Via Benzinga
News headline image
Apellis Pharmaceuticals: Q4 Earnings Insights ↗
Apellis Pharmaceuticals (NASDAQ:APLS) reported its Q4 earnings results on Monday, February 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
News headline image
Apellis Pharmaceuticals's Earnings Outlook ↗
Apellis Pharmaceuticals (NASDAQ:APLS) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement.... 
Via Benzinga
News headline image
Apellis - Sobi's Pegcetacoplan Wins European Approval For Rare Blood Disorder ↗
The European Commission has approved Swedish Orphan Biovitrum AB (OTC: BIOVF) - Apellis Pharmaceuticals Inc's (NASDAQ: APLS) Aspaveli (pegcetacoplan... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Lilly Raises Guidance, Medtronic Gets FDA Warning Letter, Decision Day For Calliditas, Genenta IPO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Vir Biotech Says COVID-19 Antibody Treatment Effective Against Omicron... 
Via Benzinga
News headline image
What 9 Analyst Ratings Have To Say About Apellis Pharmaceuticals ↗
Within the last quarter, Apellis Pharmaceuticals (NASDAQ:APLS) has observed... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For December 8, 2021 ↗
Upgrades According to Deutsche Bank, the prior rating for Goodyear Tire & Rubber Co (NASD... 
Via Benzinga
News headline image
Analyst Ratings For Apellis Pharmaceuticals ↗
Over the past 3 months, 8 analysts have published their opinion on Apellis Pharmaceuticals (NASDAQ: 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 29, 2021 ↗
Upgrades According to Odeon Capital, the prior rating for Wells Fargo & Co (NYSE: 
Via Benzinga
News headline image
The Daily Biotech Pulse: Kezar Jumps On Data, Biogen R&D Chief To Retire, Molecular Partners Wilts On COVID Trial Disappointment ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Kezar Life Sciences Reports Positive Interim Phase 2 Data For Lupus Nephritis... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Gainers Kezar Life Sciences (NASDAQ:KZR) s... 
Via Benzinga
News headline image
Where Apellis Pharmaceuticals Stands With Analysts ↗
Analysts have provided the following ratings for Apellis Pharmaceuticals (NASDAQ: 
Via Benzinga
News headline image
Cramer Likes DraftKings, Skyworks, And These Automakers ↗
On CNBC's "Mad Money Lightning Rou... 
Via Benzinga
News headline image
Better Pharmaceutical Stock: Apellis or Novartis? ↗
The pharmaceutical industry is expected to remain in the limelight as companies race to develop new medicines catering to mild diseases and critical ailments. 
Via Talk Markets
News headline image
Raymond James Upgraded This Biopharma Stock And Sees 44% Upside ↗
Raymond James has upgraded NGM Biopharmaceuticals Inc (NASDAQ: 
Via Benzinga
News headline image
60 Biggest Movers From Friday ↗
Gainers IVERIC bio, Inc. (NASDAQ: ISEE) shares surged 62.5% to close at $14.12 on Friday after Apellis Pharmaceuticals reported results from its Phase 3 DERBY and OAKS studies in... 
Via Benzinga
News headline image
Mid-Afternoon Market Update: Dow Slides Over 100 Points; Echo Global Logistics Shares Spike Higher ↗
Toward the end of trading Friday, the Dow traded down 0.31% to 34,772.74 while the NASDAQ fell 0.27% to 15,207.42. The S&P also fell, dropping 0.28% to 4,480.86. The U.S. has... 
Via Benzinga
Topics Stocks
News headline image
What 11 Analyst Ratings Have To Say About Apellis Pharmaceuticals ↗
Over the past 3 months, 11 analysts have published their opinion on Apellis Pharmaceuticals (NASDAQ: 
Via Benzinga
News headline image
8 Health Care Stocks With Unusual Options Alerts In Today's Session ↗
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges... 
Via Benzinga
News headline image
APLS Stock: The Trial Results That Have Apellis Pharmaceuticals Plunging Today ↗
Here's why investors are in full selloff mode today with APLS stock on Apellis Pharmaceuticals' latest clinical trial results. 
Via InvestorPlace
News headline image
Dow Eyes Fifth-Straight Skid, Another Weekly Drop ↗
The Dow Jones Industrial Index is giving up its earlier gains, last seen down 149 points, as investors fail to shake off the economic uncertainty that's blanketed the holiday-shortened week. 
Via Talk Markets
Topics Stocks
News headline image
Why Apellis Pharmaceutical Shares Are Plunging Today ↗
Apellis Pharmaceuticals Inc (NASDAQ: APLS) is trading lower Friday after the company announced its Phase 3 DERBY study in geographic atrophy did not meet the primary... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Gainers IVERIC bio (NASDAQ:ISEE) shares increased by 63.11% to $14.18 during Friday's regular session. IVERIC bio's stock is trading at a volume of 120.3 million... 
Via Benzinga
News headline image
Mid-Day Market Update: Crude Oil Rises Over 2%; Apellis Pharmaceuticals Shares Plunge ↗
Midway through trading Friday, the Dow traded down 0.40% to 34,739.37 while the NASDAQ fell 0.06% to 15,238.92. The S&P also fell, dropping 0.21% to 4,483.84. The U.S. has the... 
Via Benzinga
Topics Stocks
< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.